Spero Therapeutics, Inc.
675 Massachusetts Avenue, 14th Floor
Cambridge, Massachusetts 02139
March 24, 2021
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Alan Campbell
| RE: | Spero Therapeutics, Inc. |
Registration Statement on Form S-3 File No. 333-254170 |
Request for Acceleration of Effectiveness |
Ladies and Gentlemen:
In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, Spero Therapeutics, Inc. (the “Company”) hereby requests acceleration of the effective date of the Registration Statement on Form S-3 (File No. 333-254170) (the “Registration Statement”), so that it may become effective at 4:00 p.m., Washington, D.C. time on March 29, 2021 or as soon as possible thereafter.
The Company hereby authorizes Matthew J. Gardella, Esq. of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. to orally modify or withdraw this request for acceleration.
The Company respectfully requests that it be notified of such effectiveness by a telephone call to Mr. Gardella at (617) 348-1735 and that such effectiveness also be confirmed in writing. Any questions regarding this request may be addressed to Mr. Gardella.
Very truly yours,
|
SPERO THERAPEUTICS, INC.
|
/s/ Satyavrat Shukla |
Satyavrat Shukla |
Chief Financial Officer |
cc: | Spero Therapeutics, Inc.
| |
Ankit Mahadevia, M.D., President and Chief Executive Officer | ||
Tamara Joseph, Esq., Chief Legal Officer
| ||
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
| ||
Matthew J. Gardella, Esq. | ||
Matthew W. Tikonoff, Esq. | ||
Lewis J. Geffen, Esq. |
